TW205033B - - Google Patents
Download PDFInfo
- Publication number
- TW205033B TW205033B TW080108280A TW80108280A TW205033B TW 205033 B TW205033 B TW 205033B TW 080108280 A TW080108280 A TW 080108280A TW 80108280 A TW80108280 A TW 80108280A TW 205033 B TW205033 B TW 205033B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- compound
- lower alkyl
- tri
- item
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- -1 piperidino, morpholino, thiomorpholino Chemical group 0.000 claims abstract description 49
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 33
- 239000003580 lung surfactant Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 229940066294 lung surfactant Drugs 0.000 claims description 16
- 230000028327 secretion Effects 0.000 claims description 10
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 9
- 150000004997 alkyl benzene derivatives Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000009194 climbing Effects 0.000 claims description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000001555 benzenes Chemical class 0.000 claims 4
- 235000001543 Corylus americana Nutrition 0.000 claims 1
- 240000007582 Corylus avellana Species 0.000 claims 1
- 235000007466 Corylus avellana Nutrition 0.000 claims 1
- 241000269908 Platichthys flesus Species 0.000 claims 1
- 241000218206 Ranunculus Species 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 235000012149 noodles Nutrition 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000000580 secretagogue effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 32
- 210000004072 lung Anatomy 0.000 description 22
- 239000000126 substance Substances 0.000 description 20
- 239000002994 raw material Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000013078 crystal Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000007789 gas Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 201000004193 respiratory failure Diseases 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical class CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- BXCUMAUHMPSRPZ-UHFFFAOYSA-N 3,4,5-trimethylaniline Chemical compound CC1=CC(N)=CC(C)=C1C BXCUMAUHMPSRPZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- PWATWSYOIIXYMA-UHFFFAOYSA-N Pentylbenzene Chemical compound CCCCCC1=CC=CC=C1 PWATWSYOIIXYMA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000019194 Sorbus aucuparia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 206010001053 acute respiratory failure Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 235000006414 serbal de cazadores Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- JJPUFVPBTBJPNO-OLZOCXBDSA-N (1r,2s)-2-(benzylazaniumyl)cyclohexane-1-carboxylate Chemical compound OC(=O)[C@@H]1CCCC[C@@H]1NCC1=CC=CC=C1 JJPUFVPBTBJPNO-OLZOCXBDSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- FYGHSUNMUKGBRK-UHFFFAOYSA-N 1,2,3-trimethylbenzene Chemical compound CC1=CC=CC(C)=C1C FYGHSUNMUKGBRK-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- HQTOGRJJEXEVDY-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.CCCOC1=C(OC)C=C(CCN)C=C1OC HQTOGRJJEXEVDY-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- PRNZBCYBKGCOFI-UHFFFAOYSA-N 2-fluoropropane Chemical compound CC(C)F PRNZBCYBKGCOFI-UHFFFAOYSA-N 0.000 description 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
- XEFRNCLPPFDWAC-UHFFFAOYSA-N 3,4,5-trimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- FQFZBSMXFNAFTH-UHFFFAOYSA-N CNC1=CC(=CC(=C1NC)NC)N Chemical compound CNC1=CC(=CC(=C1NC)NC)N FQFZBSMXFNAFTH-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VBUZGHJTQGUGEX-UHFFFAOYSA-N azanium;toluene;chloride Chemical compound [NH4+].[Cl-].CC1=CC=CC=C1 VBUZGHJTQGUGEX-UHFFFAOYSA-N 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ARUJJNVNLJPSDO-UHFFFAOYSA-N butanamide;hydrochloride Chemical compound Cl.CCCC(N)=O ARUJJNVNLJPSDO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000008363 butyronitriles Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229960002050 hydrofluoric acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000018781 mild bronchitis Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
Description
經濟部屮央#準而员工消你合作杜印製 -^^05033 五、發明説明(1 ) 技術領域 本發明為有關 泌促進劑之三低 及其媒和物,以 背景技術 在動物之肺有 之生理活性物質 I I型上皮細胞而 全域内壁皆予以 有降低肺胞表面 用為維持呼吸機 衰竭之新生兒呼 之缺乏,另成人 減少或機能下降 呼吸衰竭狀態之 常(Journal of 1 9 8 2 ) 〇 Λ 6 Π 6 可當作翳藥,尤其肺表面活性物質之分 烷氣基苯衍生物,其鹽,其光學活性體 及這些之翳藥組成物及這些之製法等。 以稱肺表面 存在β肺表 合成及分泌 被覆之形態 張力而呈現 能上重要之 吸窘迫症候 呼吸窘迫症 之許多報告 慢性疾病也 活性物質之磷脂質為主成分 面活性物質乃主要由肺胞之 ,偽以不只肺胞領域,氣道 存在。肺表面活性物質已知 防止肺胞虛脱之作用。此作 生理機能。全引起急性呼吸 群乃起因於肺表面活性物質 候群也有肺表面活性物質之 。另H a 1 1 m a η等報告在陷入 能發生肺表面活性物質之異
Clinical Investigation 70:673-683 生菌或對異 ·έ細染質内 ii·對污物道 氣及氣性氣 全,大活在 在禦之面 , 演防作表等 扮之發肺化 尚腫喘知活 ,水氣又賦 外肺或。之 之對炎告送 脱即發報輸 。 虛。道泛毛色 抗色氣廣纖角 除角起有液要 質要引等粘重 物重或用,演 性之,作滑扮 活構染禦潤也 面機感防之泄 表禦毒之壁排 肺防病原道之 體及抗氣物 本紙張尺度边用中國Η家標毕(CNS)T4規格(210X297公;jt) 0 : ( ........................裝..:訂·:.線..... (請先閲讀背而之注意事項#堝寫本頁) Λ 6 Π 6 2〇5〇33 五、發明説明(2 ) 如上所述,肺表面活性物質因具有對氣道条之種種生 理機能,故肺表面活性物質之質之變化及量之減少可能 與多數呼吸器疾病之發症及惡化有關連。因此,促進肺 表面活性物質之分泌,則可防治種種呼吸疾病,例如嬰 兒或成人之呼吸窘迫症候群,即急性呼吸衰竭,急慢性 枝氣管炎,感染症,氣喘及慢性晬吸衰竭。 又可投予可能早産之孕婦,以預防嬰兒呼吸窘迫症候 群。 技術課題 以往,雖有將天然或依遣傅工程方法生産之肺表面活 性物質本身或當作配合劑之肺表面活性物質當作肺表面 活用(參照日本特61^」-1 3.6 9 0 ,特表昭6 3 - 5 0 1 7 9 2 ,持開平2-53798號公報但促進生體内肺表面活性物 質僅有以祛痰劑己市售之安布洛奇索Ambroxol(Merck Index第11版,第6 2 - 6 3頁,3 9 2 )發現具此活性(Post等 ,Lung 1 6 1:3 4 9 - 3 5 9, 1 9 8 3 ) 〇 他方面,以往之低烷氣基苯衍生物乃以如下式基 (請先閲讀背而之注意事項#塥寫本頁)
N Η CIC 經濟部屮央標準局貝工消奸合作社印製
本紙張尺度遑用中a國家榣毕(CNS)肀4規怙(210x297公«:) 2〇5〇33 五、發明説明(3) 吣匕、ο,ν if •Λ R 3 I A - N - B - R 4 〇 Cr*} of ]i/ 經濟部屮央標準局员工消"合作社印製 R i - N 〔式中Ri及R4各為任意被1,2或3痼鹵素,三氟甲基, Ci - 4烷氣基,Ci - 4烷基,氰基,羥基,硝基, NR 5 R e 或〇2SNRsR6 (式中Rs及R6各為氣或“-6 烷基,或共為C3_ 6聚亞甲基)敢代之,或可被 C 1 - 2伸烷二氣基在鄰接磺原子雙取代又可任意被一 個上述基取代之苯基\R2為由(CH2 )zCN(式中Z為0或 1〜4之整數),Cl - 12烷基,C3-.7環烷基,C3_ 7 環烷Ci- 4烷基,苯Ci- 4烷基,Βϋ啶基,吡啶Ci- > S 0 2 R 7 , CO· 2 R 7 > XQJJULt.及 CSMHR7(式中 R7 為 c3- 烷基,c3- 7 環院基,C3_- 7環院Cl - 4院基,苯基及苯Cl — 4 烷基所選出,且R7之任意烷基部分可任意被羥基或 c 1 - 4烷醯氣基所取代)選出,R 2之任1批啶基或苯 ____— 基部分可任意如Ri及卩4之規定取代,而R2之任意琛 烷基部分可任意以1或2傾(:1 - 4烷基所取代;R3為氫 或Cl - 4院基;A為C2 - 6伸院基,B為Cl - 4·伸院 基〕。 但在這些文獻中從未記載或暗示三低烷氣基苯衍生物 能促進肺表面活性物質之分泌。 發明之掲示 本發明者們在如此技術水準下,為開發肺表面活性物 烷基,COR 7 , C0CH2C0R7 本紙張尺度遑用中國國家楳率(CNS)T4規格(2丨0x297公Λ) (請先閱讀背而之注意事項孙塥寫本頁) Λ 6 Η 6 五、發明説明(4 ) 質之分泌促進作用優異之化合物,對種種合成化合物進 行篩選,結果發現如下式(I)新穎三低烷氣基苯衍生物 ,其鹽及其光學活性體等具有比安布洛奇索優異之肺表 面活性物質之分泌促進作用,而终於完成本發明:
R'O R30
RzO
a-ch2 ch2n<^ CONH, R4- Rs-· (I) 式中R 1 , 及 可相同或相異,各為低烷基, A 為- CH-或- Ν- , R4及R5可柑同或相異,各為低烷基,芳烷基或芳 基,但R4及R5亦可與鄰接Ν共為吡咯啶基,哌啶基, 嗎福啉基,硫嗎福啉基,或4位可被低烷基取代之呢胼 基 本發明化合物(I)其化學構造上之特徵為被如下式基 CONH, -CHCH2CH2N< R4' 或 CONH, -NCH2CH2N< R4-、. Es· (式中R4及同前)取代之三低烷氣苯。 · 反觀,上述 Journal of Medicinal Chemistry記載之 (請先閲讀背而之注意事項孙堝窍本頁) 裝::訂
C
C 經濟部中央櫺準局β工消仲合作社印製 化合物乃以式
CN chch2ch2n< ch3'. CH〆· 取代,故與本發明化合物(I )構造不同。 又前述特開昭6 2 - 2 4 0 6 5 3號公報記載之化合物,當R 2 本紙張尺度边用中國國家樣準(CNS)甲4規格(210x297公Α) ojaSftS» 205033 ^ Λ 6 ___Π_6_ 五、發明説明(5 ) 為C0NHR7時R7限為C3- 12烷基等,並不包括R7為氫 括 包 上 面 文 雖 中 物 合 化 示 所 式 通 之 報 公 該 又 Ο 物 合 化 之 例 施 實 在 例 髓 具 其 無 但 物 合 化 之 基 苯 氣 烷 三 為 物 基 h 合 苯(I化 氣物 明 甲合 發 二化。本 4-明物述 3,發合詳 示本化面 掲故穎下 只 新 基 苯 氣 I 4 或 基 苯 之 同 不 造 構 學 化 物 合 化 些 這 與 為 外 者 定 3¾ 0 行 0 除 中 義 定 之 式 通 之 文 本 指 乃 J 低 者 狀 岐 分 或 鏈 直 之 基基 2 丙戊1, 異異 , ,,基 基基丁 丙戊基 , •.甲 基基2-乙丁 , ,三基 基第丁 甲,基 有基甲 例丁1-體二 , 具第基 之,戊 J 基三 基丁第 烷異, 低,基 卩基戊 故丁新 基2- 戊2, 基 , 甲基 2 丁 ,基 基甲 戊二 基 2 甲1,- 1X > ,基 基丁 異二- 基1’ 己 , ,基 基戊 丙基 基甲 甲 3 二, 基 丁 基 甲二 基 丁 基 甲二 基 丁 基 甲二 (請先閲讀背而之注意事項#構窍本頁) 基基 丁丙 基基 乙甲 1-三- , 2 基2’ 丁 1 基 , 甲基 二丙 基基 乙乙 基 基 甲 三 基 丙 基 甲 乙 等 基 丙 基 甲- 2- 基 經濟部中央梂準局Μ工消费合作杜印製 為宜 宜 J J 基 基烷 芳芳 者 代 取 J 基 基基 丙甲 苯 2- 3 > -基 基丁 乙苯 威述3±,,ϋ
芳苯 基 丁 苯- 4 基 丙 苯 - 1Χ 基 丙 苯 基 丙 苯 苯 基 二 基 戊 苯 .本紙張尺度遑用中Β Η家樣举(CNS) Τ 4規格(210x297公放) 205033 Λ 6 Π 6 五、發明説明 苯甲基,三 本發明化 本發明化 諸如與鹽酸 酸,與甲酸 丁烯二酸, 酸,磺酸, 鹽,與麩胺 本發明化 為不對稱碩 構物之分離 本發明也 本發明化 持擻而應用 第1製法 (6 ) 苯甲基等。 合物中,宜R4及R5為低烷基,尤宜甲基。 合物(I)可形成鹽《本發明也包括這些馥, ,氫溴酸,氫碘酸,硫酸,.硝酸,磷酸等礦 ,乙酸,丙酸,草酸,丙二酸,丁二酸,反 順丁烯二酸,乳酸,_果酸,檸樣酸,酒石 苦味酸,甲磺酸,乙磺酸等有機酸之酸加成 酸,天門冬酸等酸性酸之發,及銨鹽等。 合物(I)若取代基A為 -ί;Η-時,此磺原子成 ,而有光學異構物存在。本發明包括這些異 f及其混合物。 包括本發明化合物(I )之各種物及H 〇 , 合物(I)可利用其基本骨架及種種取代基之 種種合成法來製造,其代表性製法如下。
chch2ch2n
(π) (請先間讀背而之注意事項#填寫本頁) 裝- c c 經濟部屮央標準局员工消"合作杜印製
(la) chch,ch2nc:^5) -8 本紙張尺度逡用中國國家標準(CNS) T4規怙(210X297公;«:) 2050S3 五、發明説明(7) 66 ΛΠ 第2製法 R»0 R*0 ΝΗ-ΟΗ,ΟΗ,Ν^^) RS〇 (ΙΠ) M-CNO (IV) h2o R'O CONHj R20~\~^~N_CH2CHaN (R5.,;
RsO (lb) (以上反應式中,R1 ,R2 ,R3 ,R4及Rs同前,M為氫 或齡金屬)在此所用鹺金屬可為鉀,納。 下面詳述各製法。 第1製法 式(la)中A為- 0H-之丁酷胺衍生物可將呈式(II)之對 應丁腈衍生物水解來製造。 在此反應中,不至於水解過度,故可適用以酵苛性齡 (請先閲讀背而之注意事項孙堝寫本頁) 裝. 訂- 線-
C
C 經濟部中央標準局貝工消你合作社印製 反應宜例如在第三丁醇等醇中,有NaOH或K0H等苛性 驗之存在下加熱5D°C以上》 本發明原料(II)可依上逑Journal of Medicinal Chemistry之方法或仿照其方法(參照下述反應式)而容易 獲得。 本紙張尺度遑用中《«家«毕(CNS)T4規格(2]0x2抑公;it) 205033 Λ 6 Π 6 五、發明説明(8
RlO R2 0CH2 CN + Y - CH* CH, N c ^ ) Rs(/ (V) (VI) CN R*〇-/^-CHCH2 CH2N C^ ) 經濟部中央標準局工消疗合作杜印^
RsO (Π) (上述反應式中,Ri-Rs同前,Y為鹵素)e 本發明原料(II)可令三低烷氣4乙腈(V )與取代胺乙 基鹵(VI)或其鹽反應即得<> 1 反應可在Ν,Ν -二甲基甲醯胺,二甲亞硪等對反應惰性 之有機溶劑中,用化合物(V )與其奠)耳〜莫耳化 合物(VI)或其鹽,在如NaH,NaOH, Κ0Η,乙醇納等鹼金 屬烷氣化物等驗ί若為化合物(VI)之鹽時用約2當置, i 若用非鹽時用約1當量〕,通常在室溫,必要時加溫來 進行。 第2製法 本發明化合物中,、P化合物(I b )可令、乙二胺Jft合物 -. ............ " —- ·,Λ μ 11_)與異《酸或其齡金屬取代物(iv)反應來製造。· 1 ' 反應可在無溶劑或在水,乙酸,苯,甲苯,二甲苯, 氣苯,氣仿,二氛甲烷,丙酮,四氫呋喃等有機溶劑或 這些之混液等對反應惰性之溶劑中,令化合物(III)及 (I V )大約等當量,通常在室溫,必要時加熱一短時間來 施行。 -10- 本紙張尺度边用中B Η家樣準(CNS) 1M規格(210X297公龙:) (請先閲讀背而之注意事項孙堝寫本頁) 裝- 訂_ 線· e
C r 205033 Λ6 ___nj_^_ 五、發明説明(9 ) 此製法之原料(III)可令3,4,5-三低烷氣基苯胺與J,N-二取代胺乙基鹵反應卽得。 由以上各製法所得之反應生成物可以其自由化合物, 其鹽或各種媒合物單離及精製。該鹽可予以通常之造S 反應來製造。 單離及精製可適用萃取,濃縮、,蒸發,结晶,過濾, 再结晶,各種層析等通常之化學操作來進行》 2本發明之光學異構物可適用分取得。即令欲 光學分割之jg i體與% m m合物反應,利_用所生成 2種非對映異構物之物理常數之差來分割。因本發明之 目的物為胺,故以光學活性之對掌化合物來反應作 成結晶性非對映異構物鹽,此SB以分步結晶取出難溶性 ··.·- ..... _ 鹽,將此予以複分解而得所求之光學活性體β ... 1 所用之光學活性酸如下: (請先閲讀背而之注意事項#填寫本頁) 裝- 訂_
C 經濟部屮央捣準^β工消^合作社印製 或或或或或 環瓖 胺胺 醯醯 苄苄 _ I 2 2 I I 顒反 i或或 基 - I L L 醛 -- 苄基基 甲醯醯 對苄乙 二二二
酸 石 酒酸酸 酸酸D-石石 羧羧或酒酒 己己 L D D
C 酸 磺酸 酸酸 G 仁 果烷-1否 蘋袄莰苦 本紙張尺度逡用中a國家標準(CNS)T4規格(210x297公;¢) 經濟部屮央標準局貝工消价合作杜印製 、:T,f 「 205033 i i. Λ 6 __^___R_6_ 五、發明説明(10) 等或天門冬酸,麩胺酸等酸性胺基酸。 光學分割除上述非對映異構物鹽分離法之外,尚可適 用實施 β 7 、 "~~:~ 圖面之簡單説明 ί 圖1乃示就用賁施例2之界面活性劑洗肺後之呼吸機 V能恢復作用,以»容積變化率為指標來檢討之結果縱 軸4以Tween 20〔商品名,花王Atlas公司製造,聚氣 乙烯花楸_脂肪酸酯]洗肺前之肺容積為基礎之肺容積 變化%,横軸為時間(分)。—為對照(N = 1 0 ) , —·— 安布洛奇索50mg/kg 口服(N = 5), —^―為實施例1 9之光 學活性體(+ )化合物10mg/kg 口服(N=4), —為實施 例14之化合物10mg/kg 口服(N=4), N為所用天竺鼠 之隻數,* 與對照之差異顯著性P< 0 . 05 , 為與對 照之差異顯著性P 〈O.OU 産業上之利用一可能性 本發明化合物(I),其鹽,其光學活性體及其媒和物 等具有肺表面活性物質之分泌促進作用,可當作該物質 減少,缺乏或機能下降之疾病,例如嬰兒呼吸窘迫症候群 ,成人呼吸窘迫症候群,肺水腫,急慢性呼吸衰竭,急 輕性枝氣管炎,各種感染症,氣喘等呼吸器疾病之防治 劑。 本發明化合物對肺表面活性物質之分泌促進作用可用 下述方法來確認。 -1.2- 本紙張尺度逡用中《國家«準(CNS)肀4規格(210x29^*) (請先閲請背而之注意事項#艰寫本頁) 線-
C Λ 6 η 6 205033 五、發明説明(ii) (請先閲讀背而之注意事項#堝寫本頁) 實驗例1 肺表面活性物質分泌促進作用 (實驗方法) 實驗用體重300〜350克之Hartley条雄天竺鼠。 在腹腔内投予化合物5〇Bg/ kg—次,3小時後,在戊 基巴比妥納1㈣ng/ kg麻醉下從腹主動脈及主靜脈脱血 致死,以冰冷生理食鹽水l〇Bl/ kg洗肺2次❶合併2次洗 肺液為一樣品•以4-C, lOOOrpm離心1〇分後,以上 測定肺表面活性物質。 從洗肺液上淸依Folch等之方法(Journal of Biological Chemistry 2J_6 :497-502,1957)萃取脂質,至於肺表面 活性物質之指檁,將其主成分飽和型碟Μ @基 61^11811等之方法(<1〇111*1131(^1^?1(11^86&1>(:1111: 1 6 5 1 - 1 6 5 6, 1983)萃取。卽以氣仿:甲醇(2:1)宰取脂 質,而以锇酸(ΐαο Hg/ΙΒΙ)將不飽和脾質氣化後’在中 性氣化鋁柱以氣仿:甲酵:氨水(7〇:3():2)華取飽和 型磷脂醯基瞻齡,其量以Hescort PL klt-K(S本商事 公司)测定,而求出相對於對照組(投 〇 (實驗結果) 經濟部中央標準妁员工消"合作社印製 將本發明化合物之肺表面活性物質 Mfci: 述方法檢討之結果,例如實施例/ 胃 lit 4*1窗分泌促進作用 照組呈示30%以上之肺表面活性物# ° \ 一 μ戚能恢復作用 實驗例 2 Tween 20洗肺後之呼瞄機 13- 本紙張尺度遑用+ 瓤家«準(CNS) Ή規怙(2丨0 X297公*) 經濟部中央標準扃员工消赀合作社印製 205033 Λ 6 _Π6_ 五、發明説明(12) (實驗方法) 以界面活性劑Tween 20洗肺,則肺表面活性物質被去 除而惰性化,故呼吸機能下降。將由於藥物之呼吸機能 恢復作用在Tween 20洗肺之前,後以肺容積變化率為指 標檢討。 將Hartley糸雄性天竺鼠(體重6 5 0〜7 5 0克)在胺甲酸 酯麻醉(1 . 2 g / k g ,腹腔)下以 g a 1 1 a m i n e ( 1 m g / k g ,腹 腔)使自發呼趿停止後,予以人工呼吸1 0 la 1 / k g , 6 0次 /分。以3.8% Tween 20水溶液(10ml/kg)洗肺2次。 洗後5分,經口投藥。在15cm水之壓力下之肺内容積為 肺容積變化率經時地測定。 (實驗結果) 依上述方法檢討之結果如圖1。 由圖顯示,實施例及19之化合物以安布洛奇索(對 照化合物)之1 / 5之用量也能顯著地恢復肺容積變化率, 其作用顯然比安布洛奇索為強。 以本發明化合物之一種或二種以上為有效成分之製劑 可以習知之製劑用載體或赋形劑或其他添加劑諝製成錠 劑,散劑,細粒,顆粒,膠囊,九,口服液劑(包括糖 费),注射劑,吸入劑,坐劑,經皮用液劑,軟奢,經 皮阽付劑,經粘膜貼付劑(如口腔内貼付劑),經粘膜用 液劑(如經釋用液劑)等,可經口或非經口或經由母體來 投予。 -1 4 - (請先閲讀背而之注意事項再堝寫本頁)
C 裝. 訂· 線<
C 本纸張尺度遑用中國國家樣準(CNS)肀4規格(210x297公;jt) Λ 6 Π 6 五、發明説明(13) 本發明化合物之臨床投予量乃視該病患之疾病,症狀 ,體重,年齡,性別,投予途徑等來適當地設定。 例如,嬰兒呼吸窘迫症候群時,每日靜脈注射1〜500 mg,經母體1〜5000mg,宜1〜2000fflg,其他疾病成人每 日口服1〜2000mg,宜_1〜500ag,非口服1〜2000fflg,宜 1〜500mg,作一次或分2〜4次投乎。 本發明最佳態樣以下列實施例詳述之。 實施例 1
NMe, OMe
KOH
t BuOH
conh2 MeO MeO
NMe, OMe (請先閲讀背而之注意事項再塥寫本頁) 裝- 經濟部屮央標準局员工消伢合作杜印製 於4-二甲胺基- 2-(3,4, 5-三甲氣苯基)丁腈0.84克之 2 -甲基-2 -丙醇8ml溶液中加研磨Κ0Η 1/0克而加熱回流 1小時。冷後,濾除不溶物,減壓濃縮。於殘渣加乙酸 乙酯及10%鹽酸水。分取水層而以NaOH作成強齡性。齡 性物質以乙酸乙酯萃取而依序以水/飽和食鹽水(1:1) 混液及飽和食鹽水洗濯後,以無水硫酸鈉乾燥,減壓蒸 乾。所得结晶0 . 5 9克以乙酸乙酯再結晶,得4 -二甲胺基 -2-(3,4 ,5 -三甲氣苯基)丁醯胺0 . 3 5克。 理化性狀 熔點112 °c '^) 元素分析值(Ci H24 N 2 0 4 ) 15 本紙》尺度遑用中钃國家標準(CHS) Ή規ίΜ2]0χ297公ft) 訂· 線·
C ^05033 Λ 6 η 6 五、發明説明(14) C(% ) H(% ) N(% ) 理 論 值 6 0.79 8.16 9.45 實 驗 值 6 0.56 8.11 9.39 實 施 例 2〜6 彷 實 施例1 製得下列化 合物。 實 施 例 2 conh2
NEt, OMe (請先閲讀背而之注意事項再艰寫本頁) η 4 -二乙胺基- 2- (3, 4, 5 -三甲氣苯基)&醯胺 5 . 原料:4 -二乙胺基- 2- (3 ,4,5 -三甲氣苯基)丁腈 理化性狀 質量分析值(/ z) : 3 2 4 (M+ ) 核磁共振(CDC13,TMS内部標準) ^:0. 97(6H,t, J = 7HZ), 1.7 〜2.4(4H,m) 4H. q, J = 7 H z ), 3.4 8 t , J = 8 H z ), 3. 8 1 ( 3 H, s ), 3. 8 3 ( 6 H, s), 5. 3 0 ( 1 H, b r s ), 裝- 訂_ -線- W 25 〇( %\ ( 1 H, 經濟部中央標準而ΕΧ工消-ΙΪ*合作杜印製 例 施 實 Η 1 Η 3 本紙張尺度遑用中國《家«準(CNS) T 4規格(210x297公*) 一 Λ 6 Β6 五、發明説明(15) C〇NH2
MeO
MeO OMe ι· 4-(1-咐咯啶基)-2-(3,4,5 -三甲氣苯基)丁醯胺 原料:4 -《、1 -粃咯)啶β ) - 2 - ( 3,4 , 5 -三甲氣苯基)丁腈
4, 理化性狀 質量分析值(m/ ζ 核磁共振(CDC 1 3 办:1. 7 〜2. 0 ( 4 Η , m ),1. 9 〜2. 4 ( 2 Η , m ), 2.4〜2.7(6H,m), 3. 54(1 H,t, J = 7 H z ) 3.83C3H, s), 3.86(6H, 3), 5.40 (1H, b r s ) . 5.8 7 ( 1 H. b r s ) . 6.54 (2 H, s ) 實施例4 :3 2 2 ( Μ +' ) T M S内部標準) CONH2::°〇ςτ^Ό OMe (請先閲請背而之注意事項#填寫本頁) 經濟部屮央標準局A工消仪合作社印製 4-哌啶基- 2-(3,4,5-三甲氣苯基)丁醯胺 原料:4-呢啶基-2-(3,4,5-三甲氣苯基)丁腈 理化性狀 元素分析值(CJSH28N2 04 · 0.3 EtOAc) -1 7- 本紙張尺度边用中《國家樣準(CNS)IM規格(210x297公*) Γ 2Q5Q33 A6 B6 #月Η日f止丨 經濟部中央襻率房霣工消费合作杜印製 五、發明説明(/&) C(% ) H(% ) N (% ) 理論值 63.55 8.44 7.72 實驗值 6 3.38 8.45 7.95 霣量分析值(/ z> : 3 36 (M+ ) HMR(CDC13 )3 :1.35-1.7(·, 6Η)* 1.8-2.2(», 2Η), 2.15~2.4(·, 6Η), 3.49(t, 1Η, J=7Hz), 3.81(s, 3H), 3.82(s, 6H), 6.47(s, 2H). 實施例5 conh2 OMe 4-媽福啉基- 2_(3,4,5-三甲氣苯夸)丁醯胺 原料:4-嗎福啉基- 2-(3,4 ,5-三甲氣苯基)丁脯 理化性狀 質量分析值( / z ) : 3 3 8 ( Μ + ) 核磁共振(CDC13,TMS内部榡準) ^:1.7〜2.2(2H,m),2.2〜2.5(6H,m), 3.4 8 ( 1 Hf t , J = 7 Η z ), 3. 6 〜3·8(4Η, m), 3.80(3Η, s), 3.82C6H, s), 5.52 C 2 H, b r s), 6.4 8 ( 2 H, s ) 實施例 6 CONH2 |^J|
M e 0 γ**1*^^^ N έί OMe 4,-(N-乙基-M-苯胺基)-2-(3,4,5-三甲氣苯基)丁醯胺 原料:4-(N -乙基-N-苯胺基)-2-(3,4,5 -三甲氣苯基) i 丁腈 s, -18 - 本紙張尺度適用中國國家揉準(CNS)甲4规格(210 X 297 «釐) ------------------------裝------#------線 (請先閲讀背面之注意事項再場寫本頁) 2Q5033 Λ 6 Π 6 五 發明説明 (17) 理 化 性 狀 熔 點 1 6 2-1 6 4°C 元 素 分析 值(C21 ^28 N2 〇 4 ) c(% ) H( % ) • N (% ) 理 論 值 67.72 .7 . 58 7 .52 實 驗 值 67.89 7 . 62 7 • 49 實 施 例 7 CONH2 Me0>^sIAv^ :丫〜^NMes MeO^y1 OMe 绔正·Wl CONH, -> JL ll^ NMe* *HC1 MeO^s^ OMe (請先閲讀背而之注意事項Λ-填寫本頁) 裝· 於4 -二甲胺基- 2- (3,4 ,5 -三甲氣苯基)丁醯胺10.8克 之乙酵30b1溶液加瀑鹽酸3·1及乙酵27·1之混掖,而在 室溫擻拌2小時。濾集固《而減暖乾燥,得4-二甲胺基 -2-(3, 4, 5-三甲氣苯基)丁酵胺*鹽酸鹽12. 2克β 理化性狀 訂_ 線. 經濟部中央櫺準局员工消«·合作杜印Μ 元 素 分析 值(Cifi Hzs N 2 〇 4 C 1 . 0 . 6B 2 〇) • C (% ) Η (% ) N (% ) C 1 ( % ) 理 論 值 52.43 7 • 63 8.15 1 0 . 32 實 驗 值 52.52 7 .8 1 8.15 1 0 * 5 9 將 此 在相 對瀝度74% 蒙氣 下 放 置6日, 則 成 為安定之 2 水 合 物。 熔 黏 195-1981C 依 Ca I r 1 Fis her法之含 水分 定 量 9.68重量% 水 分 ( 毎 荑 耳含 水1 . 98其耳 ) 19 本紙張尺度逡用中Β Β家猱準(CNS)甲4規怙(210x297公*) 205033 五、發明説明(18) Λ 6 η 6 仿 實 施 例 7 ,得 下列 實施例8 1 2之 化合物。 施 例 8 C〇NH2 Me〇^ Ύ 丫 -^NEt2 •HC1 ΜβΟ^ r OMe 4 - 二 乙 胺 基-2- (3,4 ,5-三甲 氣 苯 基 )丁醯胺 •鹽 原 料 : 4 - 二乙胺基- 2-(3,4, 5- 二 甲 氣苯基) 丁醯 化 性 狀 點 6 0 - 6 4。。 元 素 分 析 值(C 07 H 29 N 2 〇 4 C 1 . 1 .3 Η 2 〇) c (% ) H(°/〇 ) N ( % ) Cl (% ) 理 論 值 5 3.1 3 8.29 7 · 29 9 .23 實 驗 值 5 3.2 9 8.42 6 . 83 1 9 • 17 (請先閲讀背而之注意事項#蜞寫本頁) 實施例 CONH,
HC1 OMe 經濟部屮央櫺準局A工消"合作杜印製 4-(1-吡咯啶基)-2-(3,4 ,5 -三甲氣苯基)丁醯胺.鹽 酸鹽
原料:4-(1-吼咯啶基)-2-(3,4,5 -三甲氣苯基)丁醯胺 理化性狀 熔點 2 0 1 - 2 0 3 °C 2 0- 本紙張尺度逡用中B國家標準(CNS) T4規怙(2】0x29·/公《) 205033 λ6 η 6 發明説明 (19) 元 素 分析 值(C17H27N2 〇4 Cl ) C ( % ) Η ( % ) N(% ) Cl (% 理 論 值 56.90 7.58 7.81 9.88 實 驗 值 56.66 7.62 7.67 10.09 實施例10
MeO Me Ο c〇nh3 HCl OMe 4-哌啶基- 2-(3,4,5-三甲氣苯基)丁醯胺•鹽酸鹽 原料:4-呢啶基- 2-(3,4,5-三甲氣苯基)丁醯胺 理化性狀 熔點 192-丄 元素分析值(CisH29N2 04 Cl. 0.8H2 0) (請先閲讀背而之注意事項#堝寫本頁) 裝-
C C(% ) H(% ) N(% ) C 1 ( % 理論值 5 5.82 7.96 7.23 9.15 實驗值 5 6.02 7.86 6,93 9.28 經濟部屮央標準局貞工消扮合作社印製 HCl 實施例1 1 CON H2 ;:〇°Ρ^Ό〇· OMe 4-媽福啉基- 2-(3,4 ,5-三甲氣苯基)丁醯胺.鹽酸鹽 原料:4 -嗎福啉基- 2- (3,4,5 -三甲氣苯基)丁 _胺 本《•張尺度遑用中國Β家楳毕(CNS) Τ4規怙(2丨0x297公«)
205033 Π6 五、發明説明(20) 理化性狀 熔點 2X? - 2 2 4 °C ............. .—— >核磁共振(DMS0d6 , TMS内部標準) • 2.0 2.5 (2 Η. m ). 2. ,7 3.3 (4 H, m ). 3.2 3.6 (3 Η, m ). 3.6 1 ( 3 H. s ) t 3.7 4 (6 Η, ,s ). 3.6 4.0 ( 4 Η « m ). 6.6 4 (2 Η, ,S ). 6. 9 2 (1 Η * b r s ), 7.5 4 (1 Η, ,b r s ). 1 1. 5 5 ( 1 H * b r s ) 施 例 12 C〇NH2Me〇N^>JsN^^NJ5%JI Et OMe •HC1 4-(N-乙基-H-苯胺基)-2-(3, 4, 5-三甲氣苯基)丁醯胺 t •鹽酸鹽 (請先閱讀背而之注意事項Λ堝寫本頁) 裝- 訂· 經濟部屮央標準局貝工消价合作杜印製 原 料 • 4 - ( Ν -乙基 -N- 笨胺基 )-2 -(3,4, 5-三甲氣 丁 醯 胺 理 化 性 狀 熔 1 0 5 *—· -110 °C 元 素 分 析值 (Czl Η 29 Ν 2 〇 4 C 1 · 0 . 6 Η a 〇) C (% ) Η (% ) Ν (°/〇 ) C 1 ( % ) 理 論 值 6 0.09 7 • 25 6 .67 8.45 實 驗 值 6 0.04 7 41 6 .57 8 ..7 2 實施例1 3
線·
C 本紙張尺度逍用中國國家猱毕(CNS>T4規格(2丨0父297公龙) 205033 Λ 6 Π6 五、發明説明(21) f
Me0、,^NH* 义 〇T 〇t-
MeO
OMe γ\ 匕 。丨/ (y conh2 » X〇T MeO^^ NMe, OMe
經濟部中央標準釣β工消奸合作社印製 於3,4, 5 -三甲氣苯胺1.59克之二氛甲烷15ml溶液加無 水三氟乙酸1 0 m 1 ,而在室溫攪拌1小時後,減壓蒸除溶 劑。殘渣溶在丙麵3Qml,而加2 -氯乙基二甲胺鹽酸鹽 1.32克及磨碎K0H 7.3克。加熱回流2小時後,加水30ml 而在室溫攪拌5小時。減壓濃縮後,以1 N鹽凿稀釋作成 酸性。而以乙酸乙酯洗濯,以N a 0 H鹼化β生’成物以乙酸 >乙酯萃取而以飽和食鹽水洗濯後,以無水硫酸鈉乾燥, 減壓蒸除溶劑。殘渣在矽膠層析(k仿:甲醇=10:1), 得油狀物0 . 3 2免。將此溶在乙酸5 in 1及水5 m 1,而:滴加 . 2 3克與水3 m 1之溶液。在室溫攪拌3 . 5小時後 ,以水稀釋,而以NaOH作成鹼性。生成物以乙酸乙酯萃 取而以飽和食鹽水洗濯後,以無水硫酸納乾燥,減壓蒸 除溶劑,而從乙酸乙酯-己烷再結晶,得1-(2 -二甲胺乙 基)-1 - (3,4 , 5-三甲氣苯基)脲0 . 24克。 · , ---' 理化性狀 質量分析值(m/ z) : 2 9 8 (MH+ ) 核磁共振(CDC13, TMS内部標準) δ:2. 26(6H, s). 2. 43(2H, t , J = 7 H z ), 3.75(2H, t , J 二 7Hz). 3. 8 5 ( 6 H . s ), 3.86(3H,s). 4. 53(2H, br s ) , 6. 57 (2 H, -23 本紙張尺度逍用中曲國家榣準(CHS) T4規格(210x29•/公I) (請先閲讀背而之注意事項#艰寫本頁) 裝. 線.
C
C 205033 Λ 6η 6 五、發明説明(22) 實施例 1 4
MeO
MeO c onh2 OMe NMe, CONH; MeO ΜβΟ^^γ^ OMe NMe, *HC1 將1-(2 -二甲胺乙基)-卜(3,4, 5 -三甲氣苯基)脾220mg 溶在乙醇3ml及二乙醚15ml,而攪拌滴加 4NHC1/二B等 烷。濾集結晶而減壓乾燥,得1 - ( 2 -二甲胺乙基)-1 - ( 3 , 4,5-三甲氣苯基)脲鹽酸鹽2 3 0 mg。 理化性狀 〆--------------------------' 熔私 1 8 4 - 1 8 6 °C ) 元 素 分析 值(C14 I I 24 N 3 〇 4 Cl· Η 2 0) C ( % ) H(% ) N ( % ) C 1 ( % ) 理 論 值 4 7.79 7.45 11.94 10.08 實 驗 值 4 7.54 7.24 11.91 10.26 CONHj I .N、. 實施例 1 5 MeOx^s^NH2 OMe
MeO MeO
OMe
O (請先閲讀背而之注意事項孙塥寫本頁) 裝- 線·
C
C 經濟部屮央#準局员工消赀合作社印51
仿實施例1 3製得1 -〔 2 - ( 1 -吡咯啶基)乙基〕-1 - ( 3 , 4 , 5-三甲氣笨基)P 原料:3 , 4 , 5 -三甲氧基苯胺及1 - ( 2 -氯乙基)吡咯啶 鹽酸鹽 2 4 本紙張尺度逍用中國國家楳準(CNS)T4規怙(2丨0x297公;¢) ^05033 Λ 6 Π 6
五、發明説明(23) 理化性狀 熔點 130-131.5 °C 理論值 實驗值 實施例 1 6 C 16 Η 25 ] 〇 4 ) C(% ) H(% ) N ( % 5 9.43 7.79 12.99 5 9.29 7.76 12.83 CONH2 Me〇 OMe Γν '、 \£-,r CONH, Me ->
HC1 OMe (請先閲讀背而之注意事項再堝寫本頁)
C Ί\
Hi: v
仿實施例14製得1-〔 2-U -吡咯啶基)乙基〕 5-三甲氣苯基)P鹽酸鹽。 i 原料:l-〔2-U -吡咯啶基)乙基)-1-(3,4,5 -三甲氣 苯基)P 理化性狀 熔點 173-175.5 °C 1-(3,4 裝. 線-
C 經濟部屮央標準局员工消#合作社印製 元 素 分析 值(Cie 11¾ N 3 0 4 • 1.3(Η 3 CIO) C ( % ) H(% ) Ν ( % ) C 1 ( % ) 理 論 值 4 8.75 7.39 10.66 11.69 實 驗 值 48.70 7.25 10.73 11.75 實施例 1 7 -25- 本紙張尺度遍用中《家楳準(CNS)甲4規怙(2丨0Χ29Μ*) 205033 Α6 Β6 嫿濟部t央標攀局霣工消费合作社印製 [ 'S^ ' ^ 、 I -·五、發明説明(2+ ) L ..........—(1) MeO^ 0 Me 仿實施例13製得l-(2·贿啶乙基)-l-(3,4,5-三甲氣苯 基)脲β 原料:3,4 ,5 -三甲氣基苯胺及1-(2-氛乙基)哌啶鹽 酸鹽 理化性狀元素分析值(C17H27N3 〇4 ) C (% ) H (% ) Ν (% ) 理論值 60.51 8.07 12.45 實驗值 60.27 8.10 12.35 MMRiCDCla )5 *♦ 1.3-1.7(·, 6H)» 2.35~2.55(·, 4H), 2.50(t, 2H, J=7Hz), 3.80(t, 2H. J=7Hz). 3.83(s, 3H), 3.84(s, 6H), 6.58(s, 2H). 實施例18 CONH*^ XJ 〇*HCi ΜβΟ T OMe 仿實施例14製得1-(2-哌啶乙基)-1-(3 ,4 ,5-三甲·氣苯 基)解鹽酸鹽。 原料:1-(2 -峨症乙基)-1-(3,4,5 -三甲氣苯基)解 理化性狀 熔點 1 6 8 - 1 7 2 °C 元素分析值(CX7HZ7N3 04 · 2HC1. 0.5H20) -26 - ~ %!/)·'
------------------------装------訂------線 (請先《讀背面之注意事項再埃寫本頁) ; 本纸張尺度適用中两國家櫟準(CNS)甲4规格(210 X 297公釐〉 經濟部屮央標準局员工消许合作社印製 Λ 6 Π 6 五 、 發明説明 (25) C(% ) Η (% ) N ( % ) 理 論 值 48.69 7 .2 1 10.0 2 實 驗 值 4 9.08 7 .0 4 10.0 6 實 施 例 1 9 將 實 施 例 1所得 之4- 二 甲胺 基-2 - ( 3 ,4,5 ί甲氣苯基 )丁醯胺1 1 . 84克及 (-)- 順 -2 -苄醯胺 環 已羧 酸 9 . 75克加 熱 溶 在 14 0 η 1乙酸乙酯, 而放置1 4小 時 ,濾 集 結 晶,分 為 結 晶 及 母 液。 濾 集 之 結 晶減壓 乾燥 9 則得 11.44 克 結晶 9 經 由丙酮 12 0 m 1再結晶,得7 .8 9克结晶, 將此 從 丙酮 10 0 m I再結晶 > 得 6 . 03克 結晶( :α ] 咨=- 4 .9 . 0,( C = = 1.0 S Me 0H ))。 將 此 結 晶 浮於乙 酸乙 酯 15 0m 1中而 以 1 0 % m 酸 鈉水溶 液 洗 2 次 9 以飽和 食鹽 水 洗3次,則 得 透明 之 乙 酸乙酯 溶 液 〇 將 此 以無水 硫酸 納 乾燥 1 ,減壓蒸乾, 得2 .23克固 體 〇 將 此 溶 在乙醇 15 n 1而加濃鹽酸 0 . 75ml 9 在 4°C放置 一 夜 〇 所 析 出之結 晶予 以 吸引 收集而減壓乾燥, 得 1 · 9 6 克 (-)- 4 - 二 甲胺基 -2-( 3, 4,5- 三甲氣苯基) 丁 m 胺鹽酸 鹽 〇 * 〔 a ] '=( -60.7( •Crr- U 1 .0 ,Me 0H)) 元 素 分 析 值(Cis H 2¾ N 2 0 4 C 1*0. 6 Η 2 〇 ) C(% ) Η (% ) N(% ) C 1 (% ) 理 論 值 5 2.43 7 .6 8 8 . 1 5 10 .3 2 實 驗 值 5 2.47 7 .6 9 8 . 1 8 10 ,1 6 -2 7 I紙張尺度遑用中國國家«準(CNS) Ή規格(210X297公itt) (請先閲讀背而之注意事項再堺寫本頁) 装. 訂·
C
C 經濟部中央標準局Α工消"合作杜印製 Λ 6 Β6_ 五、發明説明(26) 熔點 2 Q 1〜2 0 3 °C 另將上述母液以15 %硪酸納水洗2次,以飽和食鹽 水洗3次後,以無水硫酸鈉乾燥而蒸乾,得3.49克固體 。將此與( + )-順-2-苄醯胺基環己羧酸2.33克加熱溶在 8 0 m 1乙酸乙酯而放置4小時後,吸引收集結晶。將所 得4 . 7 2克結晶從丙酮5 0 m 1再結晶,得3 . 3 3克结晶
( Γ «〕 Ϊ?= =+ 4 9 . 8 ( C = 1.0, M eO Η) )。將 此結晶懸浮於 乙 酸 乙 酯 10 0 m 1 ,而以1 0 %磺酸鈉水洗2次,以 飽 和食鹽 水 洗 3 -X 得 透明之 乙酸乙酯溶 液 ,將)1 tfc以無 水 硫酸鈉 乾 燥 而 減 壓 蒸 乾,得 1 . 3 7克固體 〇 將此溶在9 . 5 m 1乙醇 而 加 濃 鹽 酸 0.48ml ,在4 °C放置- -夜後 ,吸收收集結 晶 而 減 壓 乾 燥 ,得1 . 18克(+ ) -4- 二 甲胺基_ 2 -( 3 , 4 , 5-三 甲 氯 苯 基 )丁醯胺鹽酸鹽。 a 3 = +59.9( C = 1.0, Me 0Η )) 元 素 分 析 值 (C is H N 2 〇 4 Cl· 0 .5 Η 2 0) C (% ) Η ( % ) Ν ( % ) C 1 (°/〇 ) 理 論 值 5 2.71 7.67 8 . 2 0 10 .3 7 實 驗 值 5 2.60 7.62 8 . 17 10 .4 3 熔 點 2 0 1 -2 0 2 °C 所 得 之 兩 光 學活性 體以光學活 性 柱予以高速 液 體層析 9 則 均 呈 9 9 .9 %之光 學純度。 柱 : a .1 -AGP ( 4 . 0 nun i . d . X 1 0 c Β1 ) 柱 溫 度 : 2 5 °C -28- 本紙張尺度边用中Η Η家《準(CNS)甲4規格(210X297公龙) (請先閲讀背而之注意事項#堝寫本頁) 裝- 訂_ 線·
C η 205033 Λ 6 Π 6 五、發明説明(27) 溶離液:0.03M磷酸緩衝液 pH6.5 流速:0 . 8m 1/分 檢出:UV 230ηπ 處方例 1 〔吸入製劑〕 粉末吸人劑 實施例1 4之化合物 乳糖 1 m g 3 9 m g (請先閲讀背而之注意事項#堝窍本頁) 4 0 mg' 將實施例1 4之化合物1克及乳糖3 9克均勻混合而予以 微粉化及過篩後,以膠囊充《機裝入3號膠囊,作成粉 末吸入劑。 處方例2 物 合 化 -J 之 _· 4 劑 1 製劑例 入浮施 吸懸實 裝- 經濟部中央櫺準而员工消#合作社印製 酯 醏烷烷 楸甲乙 花氟氟 酸一四 油氛氣 三二 二 烷 甲 氟二 氣二 克克克克克 克
C 本紙》尺度遑用中國S家楳準(CNS) Ή規格(210X297公*) 205033 五、發明説明(28) 將實施例14之化合物150克,三油酸花楸醣酯210克均 勻地混合。所得混液0.36克裝人20ml鋁罐而插入閥裝置 ,封閉後,在加壓下用壓力氣管注入所定量之推進劑而 作成氣溶膠劑。 處方例 3 〔吸入製劑〕 溶液劑 實施例1 4之化合物 Q . 1 5克 蒸餾水 4.2 π 1 苯甲烷氯化銨 0 . 0 1克 二氯一氟甲烷 5.16克 二氛四氟乙烷 5.16克 二氣二氟甲烷 10.32克 (請先閲讀背而之注意事項#填寫本頁) 裝-
C 總量 2 5 . 0克 線- 經濟部屮央櫺準局負工消合作社印製 將實施例1 4之化合物1 5 0克,苯甲烷氯化銨1 G克,蒸 播水4. 2公升均勻混合。所得混液4.36克裝入2flml鋁罐 而插入閥裝置,封閉後,在加壓下用壓力氣管注入·所定 量之推進劑而作成氣溶膠劑。 處方例 4 錠劑 -30- 本紙》尺度遑用中B Η家«準(CNS) Ή規格(2]0夂297公《)
C 經濟部中央標準局Μ工消件合作杜印51 λ 205033 Λ 6 Β6 五、發明説明(29) 實施例1 4之化合物 10 0 乳糖 56 玉米澱粉 3 7 羥丙基纖維素 6 硬脂酸鎂 1 mg 總量 2 0 0 m g 將菁施例1 4之化合物1 0 G克,乳糖5 6克,玉米澱粉3 7 克均勻混合而加10%羥丙基纖雒素溶液60克來予以濕式 造粒。過篩後,乾燥而與硬脂酸鎂1克混合。次以8 m / m 6.4 R之臼杵打錠為錠劑β 處方例 5 膠囊 實施例14之化合物 50mg 結晶纖k素 4 Q m g 結晶乳糖 lQ9mg 硬脂酸» 1 mg 總量 2 Ο 0 m g- 將實施例1 4之化合物5 0克,结晶纖雒素4 O克,結晶乳 糖1Q9克及硬脂酸鎂1克均勻地混合,而以膠囊充填機 裝入3號嘐囊作成膠囊劑。 處方例 6 凍乾劑 -31- 本紙尺度遑用中國國家«準(CNS) Ή規格(210X297公*) (請先閲讀背而之注意事項#堝窍本頁) 裝· 訂- 線. C · 經濟部中央樑準局员工消伢合作社印3i 205033 Λ 6 η 6 五、發明説明(39 1小瓶 中 實施例 1 4之化合物 2 5扭 g D-甘露 醇 3 3 m g 總量 5 8 a g 取水80 〇 πι 1依次溶解實施例 1 4之化合物2 5克 及D- 甘露 醇33克而 加水為1公升。無菌 過濾後,每小瓶 注入 1 m 1而 凍乾作成用時溶解型之注射藥。 (請先閲讀背而之注意事項#填寫本頁) 裝· 訂_
C C · 本紙5IL尺度边用中國國家標準(CNS)Ή規格(210X297公釐)
Claims (1)
- 嫌濟#中央f屬興工消费合作杜印髮 六、t請專相範國 第8Θ1Θ8280號「三抵烷《基苯衍生物」專利案 (82年2月修正) 1. 一種如下式(I)所示三低烷《基苯衍生物,其*,其 光學活性羅及其鲽和物 R'O. CONH* R20 丄-CH2CH2〇 (I) r3o 式中R1 ·ΙΙ*及R3可相冊或相黑,各為c i - *烷基, I I A 為-CH-或-N-, 14及1^可相冊或相霣,各為Ci-*烷基,或 苯基,但R4及!^亦可典鄴接N共為毗略聢基,眯啶 基,囑禰_基。 2. 如申餹専利籠第1項之三低烷氣基苯衍生物,其中 R4輿R6可相阳或相員,各為Ci - 4烷基。 3. 如申讅專利鳙騮第1或2項之三低烷氣基苯衍生物, 其中P典118均為甲基。 4. 如申鯖専利範鼷第1或2項之三低烷氣基苯衍生物, 供衋及/或光學活性鐮。 5. 如申,辦專利範-第3項之三低烷《基苯衍生物•榛蠻 S'l 及/或光學活性繾。 6.1-(2-二甲胺乙基)-1-(3,4,5-三甲氣苯基)酴或其鹽 酸豔。 本紙張尺度遒《中面家«準(CNS)甲4现樁(2丨0 X »7 «釐> ------------------------裝------訂------線 <<M?S1INB«之注 項*$本莨>六、申請專利範國 7· 4-二甲胺基-2-(3,4,5-三甲氣笨基)丁《Γ賊或其鹽髏 窗•或道些之光學活性黼。 8. —種用於促進肺表面活性物質分泌之麵學组成《·内 含如申鯖專利範第1項之低嫌氣基苯衍生物(U, 其光學活性讎或其媒和物,及製麵容許載鼸。 9. 一種如下式(la)三抵烷«基苯衍生物之«法 R,°. CONHi R2 〇 / CHCH2 CH2 N< rS ) Rs0 (la) 之注$項再Ϊ本茛> 式中R1 ,R*及R3可相W或相真,各為Ct - 4烷基, I I A 為-CH-或-H-, R4及1(»可相两或相獬,各為Ct - 4烷基,或 苯基,但R4及1^亦可典《接Η共為巉咯«基,黷啶 基,囑裼_基》 此製法乃令如下式(II) 丁_化合物水解 R2〇^> CHCH2CHjN<®5.; •裝. 訂. -線· (式中R1 r3o r6 ro 前) (II) ϋι ID —羃如下式(lb)三低烷氣基苯衍生物之製法 r R1 R20CONHjj N-CHtCH2N^ R\ R5*· (lb) -2* 本紙flt尺度適用tji·家霉攀(CNS> ▼ 4 A格(210 X 297 i:釐) A7 B7 C7 D7 六、中請專利範* • . 式中R1 ,Ra及R3可相两或相興•各為C t - *烷基, ^ I t A 為-CH-或-Η-, R4及以可相两或相興,各為- 4烷基,成 苯基•但K4及亦可典赙接K共為毗略啶基,《(« 基·《福_基· 此覦法乃令如下式(III)乙二胺化合物 R1。 R2〇【>-NH-CH*CH2N: r3o(III) (式中R1〜冊前)典如下式(IV)興氰_或其麯金颶 取代物反· N -(CHO) (IV) (式中Μ為C或Μ金騰>。 -裝 訂. .線_ It濟*t*f屬興工消费合作杜印« i. 本纸度遍中《家霉準(CNS)甲《规格<210 χ 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28797390 | 1990-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW205033B true TW205033B (zh) | 1993-05-01 |
Family
ID=17724150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW080108280A TW205033B (zh) | 1990-10-25 | 1991-10-21 |
Country Status (15)
Country | Link |
---|---|
US (3) | US5401775A (zh) |
EP (1) | EP0555481B1 (zh) |
JP (1) | JP2534421B2 (zh) |
KR (1) | KR100223389B1 (zh) |
CN (2) | CN1061218A (zh) |
AT (1) | ATE148099T1 (zh) |
AU (1) | AU8716391A (zh) |
CA (1) | CA2094724A1 (zh) |
DE (1) | DE69124392T2 (zh) |
DK (1) | DK0555481T3 (zh) |
ES (1) | ES2100961T3 (zh) |
GR (1) | GR3022666T3 (zh) |
HU (1) | HU211226A9 (zh) |
TW (1) | TW205033B (zh) |
WO (1) | WO1992007819A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610043B1 (en) * | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
US6943198B2 (en) * | 2002-02-11 | 2005-09-13 | Edizone, Lc | Invert sugar bubbles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1238701A (fr) * | 1954-05-07 | 1960-08-19 | Nl Combinatie Chem Ind | Procédé de préparation de (méthoxy-4'-phényl)-2-dialcoylamino-2-acétamide |
US3049562A (en) * | 1961-03-09 | 1962-08-14 | American Cyanamid Co | 1-(aralkyl, lower alkylamino lower alkyl), 1-phenyl, 3, 3-dilower alkylureas |
US3917647A (en) * | 1972-04-26 | 1975-11-04 | Stauffer Chemical Co | Herbicidal compositions |
GB1574019A (en) * | 1977-01-14 | 1980-09-03 | Joullie International Sa | Therapeutically useful 3,4,5-trimethoxybenzene derivatives |
GB8603765D0 (en) * | 1986-02-15 | 1986-03-19 | Beecham Wuelfung Gmbh & Co Kg | Compounds |
JPH0259548A (ja) * | 1988-08-24 | 1990-02-28 | Hokuriku Seiyaku Co Ltd | アミド化合物 |
-
1991
- 1991-10-18 EP EP91917808A patent/EP0555481B1/en not_active Expired - Lifetime
- 1991-10-18 DK DK91917808.7T patent/DK0555481T3/da active
- 1991-10-18 US US08/050,002 patent/US5401775A/en not_active Expired - Lifetime
- 1991-10-18 CA CA002094724A patent/CA2094724A1/en not_active Abandoned
- 1991-10-18 KR KR1019930701207A patent/KR100223389B1/ko not_active IP Right Cessation
- 1991-10-18 AU AU87163/91A patent/AU8716391A/en not_active Abandoned
- 1991-10-18 ES ES91917808T patent/ES2100961T3/es not_active Expired - Lifetime
- 1991-10-18 DE DE69124392T patent/DE69124392T2/de not_active Expired - Fee Related
- 1991-10-18 AT AT91917808T patent/ATE148099T1/de not_active IP Right Cessation
- 1991-10-18 WO PCT/JP1991/001429 patent/WO1992007819A1/ja active IP Right Grant
- 1991-10-18 JP JP3516534A patent/JP2534421B2/ja not_active Expired - Fee Related
- 1991-10-21 TW TW080108280A patent/TW205033B/zh active
- 1991-10-25 CN CN91109520.9A patent/CN1061218A/zh active Pending
-
1994
- 1994-09-28 US US08/314,057 patent/US5498635A/en not_active Expired - Lifetime
-
1995
- 1995-01-28 CN CN95100367A patent/CN1034570C/zh not_active Expired - Fee Related
- 1995-06-30 HU HU95P/P00702P patent/HU211226A9/hu unknown
- 1995-11-22 US US08/562,298 patent/US5633288A/en not_active Expired - Fee Related
-
1997
- 1997-02-26 GR GR970400353T patent/GR3022666T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2100961T3 (es) | 1997-07-01 |
US5498635A (en) | 1996-03-12 |
HU211226A9 (en) | 1995-11-28 |
CN1061218A (zh) | 1992-05-20 |
EP0555481B1 (en) | 1997-01-22 |
JP2534421B2 (ja) | 1996-09-18 |
DE69124392D1 (de) | 1997-03-06 |
CA2094724A1 (en) | 1992-04-26 |
US5401775A (en) | 1995-03-28 |
EP0555481A1 (en) | 1993-08-18 |
CN1034570C (zh) | 1997-04-16 |
DE69124392T2 (de) | 1997-06-26 |
GR3022666T3 (en) | 1997-05-31 |
US5633288A (en) | 1997-05-27 |
KR100223389B1 (ko) | 1999-10-15 |
ATE148099T1 (de) | 1997-02-15 |
DK0555481T3 (da) | 1997-07-28 |
WO1992007819A1 (en) | 1992-05-14 |
CN1116200A (zh) | 1996-02-07 |
EP0555481A4 (zh) | 1994-02-23 |
AU8716391A (en) | 1992-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201733B (zh) | ||
JP3880842B2 (ja) | 1−〔(4−クロロフェニル)フェニルメチル〕ピペラジンの鏡像体およびその製造法 | |
ES2260036T3 (es) | Derivados de urea como inhibidores del receptor ccr-3. | |
CN101778831B (zh) | 哌嗪酰胺衍生物 | |
TW555738B (en) | Substituted benzamidines, their preparation and the pharmaceutical compounds for use as LTB4 antagonists containing the same | |
WO2003002554A1 (fr) | Composes de piperazine | |
US6410791B1 (en) | Nitric esters and nitrate salts of specific drugs | |
TWI758999B (zh) | 作為erk抑制劑的噻唑并內醯胺類化合物及其應用 | |
CN100494182C (zh) | 肿瘤坏死α因子信号的调节因子 | |
TW200911744A (en) | New compounds | |
US9750738B2 (en) | Arylpiperazine opioid receptor antagonists | |
NZ197678A (en) | 1-phenyl-2-(3-(2-oxo-1,2-dihydro-4h-3,1-benzoxazin-1-yl)propyl)aminoethanols | |
JPS58154538A (ja) | アルキルアミノアルコ−ル誘導体、その製造法、並びに該誘導体を有効成分とする新規薬剤 | |
JPS6226271A (ja) | キノリルグリシンアミド誘導体、その製法及び該化合物を含有する向精神薬 | |
RU2145599C1 (ru) | Производные пиперидина, способы их получения и фармацевтический препарат на их основе | |
TW205033B (zh) | ||
JP7050336B2 (ja) | 重水素化化合物及びその医薬的用途 | |
TW454005B (en) | 4-indolylpiperazinyl derivatives | |
US4645862A (en) | Isoprenylamine derivatives | |
US11504379B2 (en) | Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same | |
CN107922345A (zh) | 作为碳酸酐酶抑制剂的芳基磺酰胺化合物及其治疗用途 | |
TW509569B (en) | New salts with beneficial organoleptic properties | |
TW434234B (en) | Amide derivatives and the pharmaceutical composition thereof | |
JP2008509094A (ja) | ペンゾネート化合物,その合成方法、それを含む薬物複合物およびそれらの用途 | |
US4568765A (en) | Isoprenylamine derivatives |